In the News
SGLT-2 inhibitors linked to more diabetic ketoacidosis vs. DPP-4 inhibitors or sulfonylureas
A retrospective study found that new users of sodium-glucose cotransporter-2 (SGLT-2) inhibitors developed diabetic ketoacidosis at a rate of about 6 per 1,000 person-years, compared to 4.3 or 4.5 per 1,000 person-years with dipeptidyl peptidase-4 (DPP-4) inhibitors or sulfonylureas, respectively.
Interventions uncommon for prediabetes in primary care
A U.S. retrospective study found that while 63.4% of prediabetes patients had repeated glycemic testing over one year of follow-up, 10.4% had a primary care visit with a coded diagnosis of prediabetes, 1.0% were referred for nutrition services, and 5.4% were prescribed metformin.
Severe insulin-resistant diabetes associated with better metabolic surgery outcomes
Patients with severe insulin-resistant diabetes had better outcomes after metabolic surgery than those with mild obesity-related diabetes or severe insulin-deficient diabetes, both in terms of type 2 diabetes remission and renal function, with no additional surgical risk.
MKSAP quiz: De-escalation of therapy
This month's quiz asks readers to evaluate a 48-year-old woman who has type 2 diabetes and obesity. She reports hypoglycemia occurring approximately twice per week before lunch. Medications are empagliflozin, glipizide, liraglutide, and metformin.
Spotlight on exercise
Sports medicine experts updated their recommendations on exercise in type 2 diabetes, while a study found that physical activity was associated with lower dementia risk in patients with new type 2 diabetes, and another found that exercise might be more beneficial in the afternoon than the morning.
Recent articles address federal diabetes programs, type 1 diabetes care
The National Clinical Care Commission made 39 recommendations for improving federal diabetes programs, and the latest In the Clinic article offered advice on diagnosing and treating type 1 diabetes.
In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk
Once tirzepatide is approved by the FDA, it may be a treatment option for patients with type 2 diabetes who are overweight, have high risk for atherosclerotic cardiovascular (CV) disease, and have no gastrointestinal symptoms, an ACP Journal Club summary said.
In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality
The results of the meta-analysis support recommendations to use sodium-glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes patients who have or are at high risk for cardiovascular (CV) disease, an ACP Journal Club commentary said.
Metformin during hospitalization associated with improved outcomes in type 2 diabetes and sepsis
In a retrospective cohort study in Pennsylvania, adults with type 2 diabetes and sepsis who were exposed to metformin during hospitalization had lower 90-day mortality and better kidney outcomes than those who were not.
FDA approves new heart failure indication for SGLT-2 inhibitor
Originally approved in 2014 as a supplement to diet and exercise to improve glucose control in adults with type 2 diabetes, the sodium-glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin (Jardiance) is now approved to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.